Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017

On March 29, 2017 Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines, reported that results from preclinical studies of tipifarnib, KO-947, its development candidate targeting ERK1/2 kinases, and KO-539, its development candidate targeting the menin-MLL interaction, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2017 (Press release, Kura Oncology, MAR 29, 2017, View Source [SID1234518313]). The AACR (Free AACR Whitepaper) Annual Meeting will be held at the Walter E. Washington Convention Center in Washington, D.C. from April 1-5, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following posters will be presented during the conference. Abstracts are available at www.aacr.org.

Apr. 3, 2017, 1:00 p.m. – 5:00 p.m. EDT – Abstract 2063/20 (Poster): The farnesyltransferase inhibitor tipifarnib causes dramatic tumor regression and increases survival in murine HrasG12V driven aggressive thyroid cancers: Consequent adaptive and acquired resistance mechanisms inform combination treatments with improved responses. B. Untch et al., Memorial Sloan Kettering Cancer Center, New York, NY

Apr. 5, 2017, 8:00 a.m. – 12:00 p.m. EDT – Abstract 5168/11 (Poster): KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors. F. Burrows et al., Kura Oncology, La Jolla, Calif.

Apr. 5, 2017, 8:00 a.m. – 12:00 p.m. EDT – Abstract 5077/22 (Poster): A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias. T. Wu et al., Wellspring Biosciences, La Jolla, Calif.